Cargando…
CRISPR-Cas knockout of miR21 reduces glioma growth
Non-coding RNAs, including microRNAs (miRNAs), support the progression of glioma. miR-21 is a small, non-coding transcript involved in regulating gene expression in multiple cellular pathways, including the regulation of proliferation. High expression of miR-21 has been shown to be a major driver of...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9052041/ https://www.ncbi.nlm.nih.gov/pubmed/35572197 http://dx.doi.org/10.1016/j.omto.2022.04.001 |
_version_ | 1784696699119206400 |
---|---|
author | Nieland, Lisa van Solinge, Thomas S. Cheah, Pike See Morsett, Liza M. El Khoury, Joseph Rissman, Joseph I. Kleinstiver, Benjamin P. Broekman, Marike L.D. Breakefield, Xandra O. Abels, Erik R. |
author_facet | Nieland, Lisa van Solinge, Thomas S. Cheah, Pike See Morsett, Liza M. El Khoury, Joseph Rissman, Joseph I. Kleinstiver, Benjamin P. Broekman, Marike L.D. Breakefield, Xandra O. Abels, Erik R. |
author_sort | Nieland, Lisa |
collection | PubMed |
description | Non-coding RNAs, including microRNAs (miRNAs), support the progression of glioma. miR-21 is a small, non-coding transcript involved in regulating gene expression in multiple cellular pathways, including the regulation of proliferation. High expression of miR-21 has been shown to be a major driver of glioma growth. Manipulating the expression of miRNAs is a novel strategy in the development of therapeutics in cancer. In this study we aimed to target miR-21. Using CRISPR genome-editing technology, we disrupted the miR-21 coding sequences in glioma cells. Depletion of this miRNA resulted in the upregulation of many downstream miR-21 target mRNAs involved in proliferation. Phenotypically, CRISPR-edited glioma cells showed reduced migration, invasion, and proliferation in vitro. In immunocompetent mouse models, miR-21 knockout tumors showed reduced growth resulting in an increased overall survival. In summary, we show that by knocking out a key miRNA in glioma, these cells have decreased proliferation capacity both in vitro and in vivo. Overall, we identified miR-21 as a potential target for CRISPR-based therapeutics in glioma. |
format | Online Article Text |
id | pubmed-9052041 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Society of Gene & Cell Therapy |
record_format | MEDLINE/PubMed |
spelling | pubmed-90520412022-05-13 CRISPR-Cas knockout of miR21 reduces glioma growth Nieland, Lisa van Solinge, Thomas S. Cheah, Pike See Morsett, Liza M. El Khoury, Joseph Rissman, Joseph I. Kleinstiver, Benjamin P. Broekman, Marike L.D. Breakefield, Xandra O. Abels, Erik R. Mol Ther Oncolytics Original Article Non-coding RNAs, including microRNAs (miRNAs), support the progression of glioma. miR-21 is a small, non-coding transcript involved in regulating gene expression in multiple cellular pathways, including the regulation of proliferation. High expression of miR-21 has been shown to be a major driver of glioma growth. Manipulating the expression of miRNAs is a novel strategy in the development of therapeutics in cancer. In this study we aimed to target miR-21. Using CRISPR genome-editing technology, we disrupted the miR-21 coding sequences in glioma cells. Depletion of this miRNA resulted in the upregulation of many downstream miR-21 target mRNAs involved in proliferation. Phenotypically, CRISPR-edited glioma cells showed reduced migration, invasion, and proliferation in vitro. In immunocompetent mouse models, miR-21 knockout tumors showed reduced growth resulting in an increased overall survival. In summary, we show that by knocking out a key miRNA in glioma, these cells have decreased proliferation capacity both in vitro and in vivo. Overall, we identified miR-21 as a potential target for CRISPR-based therapeutics in glioma. American Society of Gene & Cell Therapy 2022-04-06 /pmc/articles/PMC9052041/ /pubmed/35572197 http://dx.doi.org/10.1016/j.omto.2022.04.001 Text en © 2022 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Original Article Nieland, Lisa van Solinge, Thomas S. Cheah, Pike See Morsett, Liza M. El Khoury, Joseph Rissman, Joseph I. Kleinstiver, Benjamin P. Broekman, Marike L.D. Breakefield, Xandra O. Abels, Erik R. CRISPR-Cas knockout of miR21 reduces glioma growth |
title | CRISPR-Cas knockout of miR21 reduces glioma growth |
title_full | CRISPR-Cas knockout of miR21 reduces glioma growth |
title_fullStr | CRISPR-Cas knockout of miR21 reduces glioma growth |
title_full_unstemmed | CRISPR-Cas knockout of miR21 reduces glioma growth |
title_short | CRISPR-Cas knockout of miR21 reduces glioma growth |
title_sort | crispr-cas knockout of mir21 reduces glioma growth |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9052041/ https://www.ncbi.nlm.nih.gov/pubmed/35572197 http://dx.doi.org/10.1016/j.omto.2022.04.001 |
work_keys_str_mv | AT nielandlisa crisprcasknockoutofmir21reducesgliomagrowth AT vansolingethomass crisprcasknockoutofmir21reducesgliomagrowth AT cheahpikesee crisprcasknockoutofmir21reducesgliomagrowth AT morsettlizam crisprcasknockoutofmir21reducesgliomagrowth AT elkhouryjoseph crisprcasknockoutofmir21reducesgliomagrowth AT rissmanjosephi crisprcasknockoutofmir21reducesgliomagrowth AT kleinstiverbenjaminp crisprcasknockoutofmir21reducesgliomagrowth AT broekmanmarikeld crisprcasknockoutofmir21reducesgliomagrowth AT breakefieldxandrao crisprcasknockoutofmir21reducesgliomagrowth AT abelserikr crisprcasknockoutofmir21reducesgliomagrowth |